Camden Property Trust Announces Second Quarter 2025 Dividend
HOUSTON, June 16, 2025--(BUSINESS WIRE)--The Board of Trust Managers of Camden Property Trust (NYSE:CPT) (the "Company") declared a second quarter cash dividend of $1.05 per share to holders of record as of June 30, 2025 of its Common Shares of Beneficial Interest. The dividend is to be paid on July 17, 2025.
Camden Property Trust, an S&P 500 Company, is a real estate company primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. Camden owns and operates 176 properties containing 59,670 apartment homes across the United States. Upon completion of 4 properties currently under development, the Company's portfolio will increase to 61,201 apartment homes in 180 properties. Camden has been recognized as one of the 100 Best Companies to Work For® by FORTUNE magazine for 18 consecutive years, most recently ranking #18.
For additional information, please contact Camden's Investor Relations Department at (713) 354-2787 or access our website at camdenliving.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616089381/en/
Contacts
Kim Callahan, 713-354-2549
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Why Jabil (JBL) Stock Is Up Today
Shares of electronics manufacturing services provider Jabil (NYSE:JBL) jumped 12.2% in the morning session after the company reported an impressive "beat and raise" second quarter 2025 result, which blew past analysts' revenue, earnings per share, and operating income estimates. Strong demand for its AI products more than offset weaknesses in areas like EVs, Renewables, and 5G. Looking ahead, its revenue guidance for next quarter trumped Wall Street's estimates, and it lifted its full-year sales and EPS outlook. Full-year free cash flow estimate was also maintained at $1.2 billion+, backing management's resolve to return more value to shareholders. Zooming out, we think this was a strong quarter. Is now the time to buy Jabil? Access our full analysis report here, it's free. Jabil's shares are somewhat volatile and have had 13 moves greater than 5% over the last year. But moves this big are rare even for Jabil and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 9% on the news that the company reported strong first-quarter (Q2 2025) results that significantly blew past analysts' revenue and EPS estimates. The company attributed the strong growth to demand for its capital equipment, cloud and data center businesses. Despite the outperformance, profits came in softer than expected due to restructuring and severance costs. This helped Jabil beat analysts' EPS expectations. Overall, this was a decent quarter, which showed that the company was staying on track. Jabil is up 41.7% since the beginning of the year, and at $202.33 per share, has set a new 52-week high. Investors who bought $1,000 worth of Jabil's shares 5 years ago would now be looking at an investment worth $6,157. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Edge Case Appoints Lt. Gen. (Ret.) Ross Coffman to Board of Directors
PITTSBURGH, June 17, 2025--(BUSINESS WIRE)--Edge Case, the trusted technical partner for teams building and operating frontier technology and safety-critical systems, is proud to announce that Lt. Gen. (Ret.) Ross Coffman has joined its Board of Directors. Ross brings a decorated career in the U.S. Army, where he most recently served as Deputy Commanding General of the U.S. Army Futures Command and previously led the Next Generation Combat Vehicle Cross Functional Team. His leadership was instrumental in modernizing the Army's approach to autonomy, robotics, and complex systems making him uniquely positioned to support Edge Case's mission at the cutting edge of frontier technology. As Edge Case enters a new phase of growth, momentum is building across both commercial and defense markets. The company is actively shaping how teams approach DevSafeOps, integrating safety assurance throughout the product lifecycle from development through deployment and operations. Ross's deep operational experience and future-focused mindset align perfectly with Edge Case's vision for building trust into frontier technologies from day one. "Frontier technologies like AI and autonomous systems are transforming both the battlefield and the boardroom. Edge Case brings deep technical expertise, a safety-first mindset, and a bold sense of purpose, which is exactly what's needed to lead responsibly in this rapidly evolving field. I'm honored to join the Board as they continue to define what 'safe enough' truly means in the real world." – Lt. Gen Coffman With Ross joining the board, Edge Case is doubling down on its commitment to advancing the safety of emerging technologies not just as a regulatory requirement, but as a strategic differentiator. "Ross's leadership has shaped how the U.S. military approaches frontier technologies like AI, robotics, and autonomy. His strategic insight will be invaluable as Edge Case helps define what safe and trusted innovation looks like at the speed and scale demanded by modern defense." - Nathan Parker, CEO, Edge Case This appointment reflects Edge Case's continued investment in combining deep technical rigor with real-world leadership. As autonomous systems increasingly take on complex roles in commercial and defense, Edge Case remains committed to helping customers deliver bold innovation with safety as foundational. View source version on Contacts info@ Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Why Verve Therapeutics Stock Is Skyrocketing Today
Eli Lilly plans to acquire Verve for up to $1.3 billion. Lilly wants Verve because of the potential for base-editing therapy VERVE-102. 10 stocks we like better than Verve Therapeutics › Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly to acquire Verve." Lilly offered $10.50 per share in cash, payable at the closing of the transaction. This represents a premium of around 113% to the 30-day volume-weighted average trading price of Verve stock for the period ending June 16, 2025. In addition, Verve shareholders will receive one nontradable contingent value right (CVR) per share owned that could entitle them to receive another $3 per share when the first patient is dosed with VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a U.S. phase 3 clinical trial within 10 years of the closing or termination of the CVR. The total purchase price if the CVR is paid amounts to around $1.3 billion. Verve is a leader in base editing, a type of gene editing that supports precise editing of a single base within DNA. The company's crown jewel is VERVE-102, a base-editing therapy that's currently being evaluated in a phase 1b clinical study for treating ASCVD. Although VERVE-102 is still in early-stage testing, Lilly liked what it saw with the experimental therapy. Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said, "VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient population and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment." Usually, when an acquisition of a clinical-stage drugmaker is announced, investors don't have much incentive to buy the small biotech stock before the deal closes. In this case, though, the CVR that's part of Lilly's purchase agreement could be appealing to some investors willing to bet on the success of VERVE-102. Although there's a risk that the base-editing therapy will fail before it advances to phase 3 testing, it's not too late to buy Verve stock. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Verve Therapeutics Stock Is Skyrocketing Today was originally published by The Motley Fool
